Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease

International Journal of Cardiology

Volumn 153, Issue 2, 2011, Pages 141-147

  Bays, Harold E ^a   Conard, Scott E ^b   Leiter, Lawrence A ^c   Bird, Steven R ^d   Lowe, Robert S ^d   Tershakovec, Andrew M ^d  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Atorvastatin; Cholesterol; Ezetimibe

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; ETHNIC DIFFERENCE; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AZETIDINES; CONTINENTAL POPULATION GROUPS; CORONARY DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRROLES; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 81755171398     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.08.043     Document Type: Article

References (46)

1. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
2. D. Lloyd-Jones, R.J. Adams, and T.M. Brown Heart disease and stroke statistics - 2010 update. A report from the American Heart Association Circulation 121 2010 E46 E215
3. J.G. Robinson Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly opportunities and challenges Drugs Aging 26 2009 917 931
4. F. Rollini, L. Mfeukeu, and M.G. Modena Assessing coronary heart disease in women Maturitas 62 2009 243 247
5. L.J. Shaw, R. Bugiardini, and C.N. Merz Women and ischemic heart disease: evolving knowledge J Am Coll Cardiol 54 2009 1561 1575
6. F.K. Welty Cardiovascular disease and dyslipidemia in women Arch Intern Med 161 2001 514 522
7. K.C. Ferdinand Coronary artery disease in minority racial and ethnic groups in the United States Am J Cardiol 97 2006 12A 19A
8. D.W. Jones, L.E. Chambless, and A.R. Folsom Risk factors for coronary heart disease in African Americans - the Atherosclerosis Risk in Communities Study, 1987-1997 Arch Intern Med 162 2002 2565 2571
9. J.C. LaRosa, and C.D. Brown Cardiovascular risk factors in minorities Am J Med 118 2005 1314 1322
10. M.H. Davidson, C.M. Ballantyne, and B. Kerzner Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia Int J Clin Pract 58 2004 746 755
11. T. Feldman, M. Davidson, and A. Shah Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post hoc analysis of subpopulations from three pooled clinical trials Clin Ther 28 2006 849 859
12. A.C. Goldberg, A. Sapre, J. Liu, R. Capece, and Y.B. Mitchel Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial Mayo Clin Proc 79 2004 620 629
13. L. Lipka, P. Sager, J. Strony, B. Yang, R. Suresh, and E. Veltri Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia Drugs Aging 21 2004 1025 1032
14. S. Bennett, P. Sager, L. Lipka, L. Melani, R. Suresh, and E. Veltri Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men J Womens Health Larchmt 13 2004 1101 1107
15. T.A. Pearson, M.A. Denke, and P.E. McBride Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial Mayo Clin Proc 81 2006 1177 1185
16. L. Ose, A. Shah, and M.J. Davies Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis Curr Med Res Opin 22 2006 823 835
17. S.E. Conard, H.E. Bays, and L.A. Leiter Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease Am J Cardiol 102 2008 1489 1494
18. L.A. Leiter, H. Bays, and S. Conard Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease Am J Cardiol 102 2008 1495 1501
19. M.M. Cotreau, L.L. Von Moltke, and D.J. Greenblatt The influence of age and sex on the clearance of cytochrome P450 3A substrates Clin Pharmacokinet 44 2005 33 60
20. H. Bays Ezetimibe Expert Opin Investig Drugs 11 2002 1587 1604
21. Zetia (ezetimibe) tablets [package insert] 2009 Merck/Schering-Plough Pharmaceuticals North Wales, PA
22. D.M. Gibson, N.J. Bron, A. Richens, N.J. Hounslow, A.J. Sedman, and L.R. Whitfield Effect of age and gender on pharmacokinetics of atorvastatin in humans J Clin Pharmacol 36 1996 242 246
23. Lipitor (atorvastatin calcium) tablets for oral administration [package insert] 2009; USA: Dublin, Ireland: Pfizer Ireland Pharmaceuticals. Distributed by Parke-Davis Division of Pfizer Inc., New York, NY; 2009.
24. M.J. Tikkanen, I. Holme, and N.B. Cater Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged < 65 versus > = 65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study) Am J Cardiol 103 2009 577 582
25. T. Kosoglou, P. Statkevich, A.O. Johnson-Levonas, J.F. Paolini, A.J. Bergman, and K.B. Alton Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions Clin Pharmacokinet 44 2005 467 494
26. E. Stein Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor Eur Heart J Suppl 3 2001 E11 E16
27. J.G. Robinson, M. Davidson, and A. Shah Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65-74 and 75 years and older Aging Health 3 2007 691 705
28. C.L. Shear, F.A. Franklin, and S. Stinnett Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins Circulation 85 1992 1293 1303
29. J.A. Simon, F. Lin, and S.B. Hulley Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) study Am J Cardiol 97 2006 843 850
30. L. Streja, C.J. Packard, J. Shepherd, S. Cobbe, and I. Ford Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS) Am J Cardiol 90 2002 731 736
31. M.H. Davidson, M.A. Dillon, and B. Gordon Colesevelam hydrochloride (Cholestagel) - a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects Arch Intern Med 159 1999 1893 1900
32. A. Keech, R.J. Simes, and P. Barter Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 2005 1 13
33. N. Jochmann, K. Stangl, E. Garbe, G. Baumann, and V. Stangl Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases Eur Heart J 26 2005 1585 1595
34. R.Z. Harris, L.Z. Benet, and J.B. Schwartz Gender effects in pharmacokinetics and pharmacodynamics Drugs 50 1995 222 239
35. R.M. Krauss, L.M. Mangravite, and J.D. Smith Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment Circulation 117 2008 1537 1544
36. R.G. Hutchinson, R.L. Watson, and C.E. Davis Racial differences in risk factors for atherosclerosis - the ARIC study Angiology 48 1997 279 290
37. K.C. Ferdinand, L.T. Clark, and K.E. Watson Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial Am J Cardiol 97 2006 229 235
38. R.A. Rodney, D. Sugimoto, and B. Wagman Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia J Natl Med Assoc 98 2006 772 778
39. C.M. Ballantyne, J. Houri, and A. Notarbartolo Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial Circulation 107 2003 2409 2415
40. C.M. Ballantyne, M.A. Blazing, T.R. King, W.E. Brady, and J. Palmisano Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia Am J Cardiol 93 2004 1487 1494
41. S.S. Daskalopoulou, and D.P. Mikhailidis Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe Curr Med Res Opin 22 2006 511 528
42. D.P. Mikhailidis, G.C. Sibbring, C.M. Ballantyne, G.M. Davies, and A.L. Catapano Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy Curr Med Res Opin 23 2007 2009 2026
43. E. Stein, S. Stender, and P. Mata Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin Am Heart J 148 2004 447 455
44. C. Baigent, and M. Landry Study of Heart and Renal Protection (SHARP) Kidney Int Suppl 2003 S207 S210
45. C.P. Cannon, R.P. Giugliano, and M.A. Blazing Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes Am Heart J 156 2008 826 832
46. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150